The nation's leading industry group for regenerative medicine today called for a clearer federal pathway to help bring stem cell products to the marketplace.
The Alliance for Regenerative Medicine (ARM), which has 240 business, academic and patient advocacy members, testified today at a Food and Drug Administration hearing into proposals for more regulation of the stem cell industry. Randy Mills, president of the California stem cell agency, is scheduled to speak later today.
In remarks prepared for delivery, Michael Werner, executive director of the group, said,
"What all manufacturers have in common...is that they seek a clear and predictable regulatory pathway to market. In general, ARM believes that while the draft guidances are a positive step forward, they still leave some questions unanswered regarding interpretation of regulations . Consequently, ARM believes that when FDA finalizes these guidances, it should take actions to provide even more clarity."Werner went on to make specific suggestions for more explanation on requirements for product characterization and associated claims for each type of product.
The full text of his remarks can be found here. You can find additional information in the texts of the group's comments that were submitted in writing on "minimal manipulation" here and and on "homologous use" here.
The two-day hearing is being broadcast live on the Internet.
No comments:
Post a Comment